Antidyslipidemic activity of extract of Eugenia jambolana (EJ, Jamun fruit) in adult Charles Foster rats of both sexes was studied and compared with that of Atorvastatin (Atorva). 4 groups were made [Gp 1-Control group (no drug), only high fat diet (HFD); Gp 2-HFD +EJ (evaluation of role of EJ in the prevention of dyslipidemia); Gps 3 & 4-only HFD]. This was the phase of disease production, lasting for 7 weeks, in which we also evaluated the preventive role of EJ. Thereafter, therapy phase started, which lasted for 90 days [Gp 1-Control group (no drug). Only HFD; Gp 3-HFD+ Atorva; Gp 4-HFD+EJ]. Parameters tested were TC (total cholesterol), TG (triglycerides), LDL (low density lipoproteins) and HDL (high density lipoproteins). During the prevention/ disease production phase, EJ brought an improvement in TC level as compared to control group, which was statistically not significant; but improvements in TG, LDL & HDL levels were significant. Moreover, in the therapy phase, EJ brought significant improvement in all the parameters. It means to say, EJ takes some time in the initiation of a significant response-as we know that natural products take some time for the onset of their therapeutic effects. During therapy phase, Atorva was slightly more effective than EJ. Therefore, Eugenia jambolana, as a low-cost herbal therapy, offers an inexpensive, safe & effective measure to combat major public health problems viz dyslipidemia/ Coronary Artery Disease/ Atherosclerosis.
INTRODUCTION:Globally, the rate of premature deaths from cardiovascular diseases (CVD) is at an all-time high 1 . Over the past 30 years, the number of CVD fatalities in Asia has nearly doubled from 5.6 million to 10.8 million 2 . As dyslipidemia develops, the risk of CVD rises by two times 1 . Currently, in this world, dyslipidemia is to blame for about 4 million deaths from CVD.